Researchers from Hibercell Inc. presented preclinical data for the eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitor HC-5404, currently in phase I development for the treatment of solid tumors (NCT04834778).
Human natural killer (NK) cells play an essential role in tumor surveillance and can attack malignant cells in an antigen-independent manner. Because of this, allogeneic NK cells can be engineered as off-the-shelf therapies and may be used to target different hematological malignancies or solid tumors.
Voltron Therapeutics Inc., a portfolio company of Lucius Partners LLC, has signed a new sponsored research agreement (SRA) with the Vaccine and Immunotherapy Center at Massachusetts General Hospital (MGH), Harvard Medical School to initiate a preclinical immuno-oncology study targeting prostate stem cell antigen (PSCA) in prostate, renal cell and urothelial cancers.
A French surgical team has performed a robot-assisted kidney auto-transplantation with ex situ tumorectomies for renal cell cancer. This is the world first use of the fourth generation Da Vinci Xi surgical robot from Sunnyvale, Calif.-based Intuitive Surgical Inc. to perform kidney explanation and autotransplantation with removal of multiple and complex tumors outside of a patient's body.
Repeat expansions of two or more base pairs cause dozens of neurological disorders – Huntington’s disease, which is caused by an expansion of the triplet CAG in the coding sequence for huntingtin, is perhaps the most famous one. Now, investigators at Stanford University have shown that cancer genomes, too, frequently feature repeat expansions.
Cofactor Genomics Inc. opened the non-small-cell lung cancer portion of its study of the Oncoprism test, which predicts response to immunotherapy. The Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies (PREDAPT) trial will study the test’s predictive ability in 11 cancers in total.
Repeat expansions of two or more base pairs cause dozens of neurological disorders – Huntington’s disease, which is caused by an expansion of the triplet CAG in the coding sequence for huntingtin, is perhaps the most famous one. Now, investigators at Stanford University have shown that cancer genomes, too, frequently feature repeat expansions.
Vincerx Pharma Inc. has received FDA clearance of its IND application for VIP-236, a small molecule-drug conjugate (SMDC) for the treatment of advanced solid tumors. A first-in-human study for advanced or metastatic solid tumors is expected to start in the first quarter of next year.
Molecure SA has received clearance from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products to conduct the first clinical trial of OATD-02.
While no one can tell the future, a panel of autoantibodies developed by researchers at New York University Grossman School of Medicine and Perlmutter Cancer Center may give physicians a much better idea about how a patient will respond to immunotherapy. That could help improve therapy selection by accurately predicting whether a patient’s cancer will recur following immunotherapy or they will experience autoimmune side effects as a result of treatment, a study published in Clinical Cancer Research on Sept. 15 found.